دورية أكاديمية
أعرض في EDS

Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran

التفاصيل البيبلوغرافية
العنوان: Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
المؤلفون: Amir Hashemi-meshkini, Amirmohammad Tajik, Nayyereh Ayati, Shekoufeh Nikfar, Reza Koochak, Saeed Yaghoubifard, Azam Abbasi, Mehdi Varmaghani
المصدر: Journal of Tehran University Heart Center, Vol 18, Iss 2 (2023)
بيانات النشر: Tehran University of Medical Sciences, 2023.
سنة النشر: 2023
المجموعة: LCC:Diseases of the circulatory (Cardiovascular) system
مصطلحات موضوعية: Acute coronary syndrome, Ticagrelor, Clopidogrel, Cost-effectiveness analysis, Diseases of the circulatory (Cardiovascular) system, RC666-701
الوصف: Background: The present study aimed to determine the cost-effectiveness of ticagrelor compared with clopidogrel in Iranian patients with acute coronary syndrome (ACS). Methods: A 1-year decision tree model combined with a 20-year Markov transition model was used to simulate the long-term cost and effectiveness of both ticagrelor and clopidogrel in Iran based on an Iranian payer’s perspective. Clinical efficacy data were extracted from the PLATO trial and other published studies. Costs were estimated based on local prices in public sectors. Deterministic and probabilistic sensitivity analyses were used to test the robustness of base-case results over the uncertainties of model inputs. All calculations, analyses, and modeling were done in TreeAge 2011 and Microsoft Excel 2013. Results: Compared with clopidogrel, the treatment of Iranian ACS patients with ticagrelor for 20 years resulted in an additional cost of US$ 2.39 in a hypothetical cohort of 1000 patients. However, ticagrelor led to 7.2 quality-adjusted life-years (QALYs) gained per 1000 hypothetical patients. Accordingly, the estimated incremental cost-effectiveness ratio for this analysis was US$ 332.032 per 1 QALY gained. Conclusion: Ticagrelor was a cost-effective antiplatelet medicine compared with clopidogrel in Iranian patients with ACS. This could help Iran’s policymakers to allocate resources more efficiently to ACS.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1735-8620
2008-2371
Relation: https://jthc.tums.ac.ir/index.php/jthc/article/view/1800; https://doaj.org/toc/1735-8620; https://doaj.org/toc/2008-2371
DOI: 10.18502/jthc.v18i2.13318
URL الوصول: https://doaj.org/article/ebff7df017e44441934c36d9c9e898f4
رقم الأكسشن: edsdoj.bff7df017e44441934c36d9c9e898f4
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:17358620
20082371
DOI:10.18502/jthc.v18i2.13318